Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sopherion Therapeutics, a biopharmaceutical company engaged in the development and commercialization of anticancer therapies, has appointed Marcel Rozencweig as its new senior executive vice president for clinical affairs.
Subscribe to our email newsletter
Prior to joining Sopherion, Dr Rozencweig was a key clinical development consultant to the company and a member of the Sopherion protocol development team for Myocet.
Dr Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including vice president of oncology, infectious diseases and immunology clinical research; and vice president of strategic planning and portfolio management.
Ronald Goldfarb, president and CEO of Sopherion, said: “Dr Rozencweig’s world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward. His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol and Paraplatin.”